P+P Pöllath + Partners advised vasopharm GmbH as part of a financing round amounting to EUR 20 million.

Alongside existing investors such as Entrepreneurs Fund, Heidelberg Capital Private Equity, Bayern Kapital and funds, advised by Hanseatic Asset Management Ltd., investor Fort Rock Capital participated in the financing round. The venture partner of Fort Rock Capital, Mario Alberto Accardi, will remain an advisory board member.

The vasopharm GmbH, based in Wurzburg, Bavaria, is a biopharmaceutical company focusing on the research and development of new treatments for the treatment of cerebral and cardiovascular diseases and their consequences. The company's core competence lies in the development of active ingredients for controlling nitric oxide levels by modulation of NO synthases.

P+P Munich partner Michael Inhester advised vasopharm GmbH on corporate and financing issues.